• $11.1M
    Market Cap
  • -67.24%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
21,796
N/A
Cost of Revenue
N/A
N/A
Gross Profit
17,565
N/A
Sales and Marketing Expense
817,554
N/A
Research and Development Expense
N/A
N/A
Depreciation and Amortization Expense
N/A
N/A
Total Operating Expenses
8.9M
N/A
Operating Profit
-8.9M
N/A
Interest Income
N/A
N/A
Interest Expense
-1,064
N/A
Interest Income and Expense and Net
-1,064
N/A
Total Nonoperating Income and Expense
47,912
N/A
Income before Taxes
-8.9M
N/A
Income Taxes
N/A
N/A
Extraordinary Items
N/A
N/A
Net Income
N/A
N/A
Net Income from Continuing Operations Applicable to Common
N/A
N/A
Basic EPS and Net Income
-0.25
N/A
Diluted EPS and Net Income
-0.25
N/A
Basic Weighted Average Shares
34.6M
N/A
Diluted Weighted Average Shares
34.6M
N/A
Balance Sheet
Cash and Cash Equivalents
3.8M
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
3.8M
N/A
Total Current Assets
4.8M
N/A
Accumulated Depreciation
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
Total Long-Term Assets
3,783
N/A
Total Assets
5.6M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
5.3M
N/A
Total Current Liabilities
7.4M
N/A
Total Long-Term Debt
4.2M
N/A
Total Long-Term Liabilities
21,247
N/A
Total Liabilities
7.4M
N/A
Retained Earnings
-34.7M
N/A
Total Stockholders Equity
N/A
N/A
Total Shares Outstanding
34.4M
N/A
Cash Flow
Cash from Operating Activities
-5.4M
N/A
Capital Expenditures
N/A
N/A
Cash from Investing Activities
N/A
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
5.4M
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow